Study of the Efficacy and Safety of Pegol-Sihematide for Anemia in Patients With Chronic Kidney Disease on Dialysis
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 372 participants.
Also called NCT03902691
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 372 participants
- Registry
-
NCT03902691
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT03902691. Randomized; double masking; primary purpose treatment. Start 2019-05-15 (actual); primary completion 2021-02-28 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study of the Efficacy and Safety of Pegol-Sihematide for Anemia in Patients With Chronic Kidney Disease on Dialysis
- Condition
- Chronic Kidney Diseases
- Intervention (Drug)
- Pegol-Sihematide
- Intervention (Drug)
- ESPO
- Lead sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Record details
- Record id
cardio:ct-nct03902691- Content hash
3f86bd24ba005810df8abad23336c37be852e7ab47c83264dad2dc625ca8b4da